网络药理学与实验验证揭示肾康宁胶囊对慢性肾炎的缓解作用
肾康宁胶囊(SKN)由八味中药组成,临床用于治疗慢性肾小球肾炎(CGN),但机制不明。本研究通过阿霉素(ADR)诱导小鼠局灶节段性肾小球硬化模型,结合网络药理学预测与RT-PCR、Western-blot及ELISA验证,发现SKN(1、10 g/kg)改善肾病,机制涉及抑制NF-κB活化、激活Nrf2通路,且黄芪(HQ)贡献主要疗效。
要点
- SKN(1、10 g/kg)可改善ADR诱导的小鼠肾病。
- SKN通过抑制NF-κB、激活Nrf2减轻炎症和氧化应激。
- 黄芪是SKN改善ADR肾病的主要贡献药材。
核心结论
- SKN通过抑制肾脏炎症和氧化应激损伤、阻断NF-κB活化并激活Nrf2信号通路,改善ADR诱导的小鼠肾病。
- 黄芪对SKN改善ADR诱导的小鼠肾病起主要贡献。
研究设计与样本
- 研究采用ADR静脉注射小鼠诱导局灶节段性肾小球硬化(FSGS)模型。
- 整合网络药理学分析与实验验证(RT-PCR、Western-blot、ELISA)。
主要发现
- SKN(1、10 g/kg)改善ADR诱导的小鼠肾病。
- 网络药理学预测炎症和氧化应激关键参与SKN的肾脏保护作用。
- SKN降低NF-κB活化及部分促炎细胞因子表达,增加Nrf2活化及其下游基因表达。
- SKN恢复足细胞相关蛋白podocin和synaptopodin的降低表达。
- 毒性药物丹附片(DFP)对SKN改善ADR肾病无贡献;黄芪(HQ)贡献主要疗效。
临床怎么用
- SKN可用于慢性肾小球肾炎治疗,其机制与调控NF-κB/Nrf2通路相关。
- 黄芪是SKN疗效的主要贡献药材,组方中应关注其质量与剂量。
局限性
- 研究仅基于ADR诱导的小鼠模型,结论需临床研究进一步验证。
- 网络药理学预测结果需更多实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Shenkangning (SKN), a Chinese patent medicine composed by eight Chinese medicinal herbs, is commonly applied to treat chronic glomerulonephritis (CGN) in clinic. However, its mechanism is still not clear now. AIM OF THE STUDY: This study is designed to evaluate the SKN-provided alleviation on adriamycin (ADR)-induced nephropathy, to reveal its mechanism by integrating network pharmacology analysis and experimental evidences, and to further find the main drug that makes a major contribution to its efficacy. MATERIALS AND METHODS: ADR was intravenously injected to mice to induce focal segmental glomerulosclerosis (FSGS). Renal histological evaluation was conducted. The level of urinary protein, and serum amounts of creatinine, urea nitrogen (BUN) and albumin were detected. The potential mechanisms were predicted by network pharmacology analysis and further validated by Real-time polymerase chain reaction (RT-PCR), Western-blot and enzyme-linked immunosorbent assay (ELISA). RESULTS: SKN (1, 10 g/kg) improved ADR-induced nephropathy in mice. Network pharmacology results predicted that inflammation and oxidative stress were crucially involved in the SKN-provided amelioration on nephropathy. SKN reduced the activation of nuclear factor-κB (NF-κB) and the expression of some pro-inflammatory cytokines, and increased the activation of nuclear factor erythroid 2-related factor 2 (Nrf2) and the expression of its downstream genes in ADR-induced nephropathy in mice. Furthermore, SKN also restored the reduced expression of both podocin and synaptopodin, which are podocyte-associated proteins. Further results showed that the toxic drug Danfupian (DFP) had no contribution to the SKN-provided alleviation on ADR-induced nephropathy in mice. After integrating the results from evaluating anti-inflammation, anti-oxidant and anti-injury of podocytes in vitro and from comparing the activity of the whole SKN and SKN without Astragali Radix (Huangqi, HQ) in vivo, we found that HQ played a crucial contribution to the SKN-provided amelioration on ADR-induced nephropathy in mice. CONCLUSION: SKN improved ADR-induced nephropathy through suppressing renal inflammation and oxidative stress injury via abrogating NF-κB activation and activating Nrf2 signaling pathway. HQ played a main contribution to the SKN-provided amelioration on ADR-induced nephropathy.
引用
- Wei M, Qiu Z, Li H, et al. Integrating network pharmacology approach and experimental validation to reveal the alleviation of Shenkangning capsule on chronic nephritis. J Ethnopharmacol. 2022. PMID: 36057408. doi:10.1016/j.jep.2022.115676
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。